Targeting mTORC2 component rictor inhibits cell proliferation and promotes apoptosis in gastric cancer

Yu-Hai Bian1, Jia Xu1, Wen-Yi Zhao1

  • 1Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghai, China.

Insights

Rictor, a key component of mTORC2, promotes gastric cancer progression and metastasis. Inhibiting Rictor suppressed tumor growth and enhanced apoptosis, suggesting dual targeting of mTORC1 and mTORC2 for gastric cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Mammalian target of rapamycin (mTOR) kinase is crucial in gastric cancer progression.
  • mTOR complex1 (mTORC1) roles are known, but mTOR complex2 (mTORC2) and Rictor functions are unclear.

Purpose of the Study:

  • Investigate the clinical significance of Rictor expression in gastric cancer.
  • Elucidate Rictor's roles in gastric cancer cell proliferation, apoptosis, migration, and invasion.

Main Methods:

  • Immunohistochemical analysis of Rictor in 391 gastric cancer tissue samples.
  • RNA interference (sh-RNA) to down-regulate Rictor in gastric cancer cell lines (SGC7901, MGC803).
  • Evaluation of cell proliferation, apoptosis, cell cycle, migration, and invasion.

Main Results:

  • Rictor overexpression correlated with larger tumor size, deeper invasion, lymph node metastasis, advanced TNM stage, and poorer survival.
  • Rictor down-regulation inhibited gastric cancer cell proliferation, migration, and invasion.
  • Rictor knockdown reduced cell cycle progression, enhanced apoptosis, and sensitized cells to rapamycin by blocking Akt feedback activation.

Conclusions:

  • Rictor is a significant mediator of gastric cancer progression and metastasis.
  • Targeting both mTORC1 and mTORC2 (via Rictor) offers a potential therapeutic strategy for gastric cancer.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K